GoAI
Get started
MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.38

$0.00 · 0.00%

Aug 21, 4:00 PM ET

MXCT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

43

Fair Value

Momentum

63

Gaining

Sentiment

54

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Maher Masoud
Listed since
Jul 29, 2021
Employees
91

Market position

Day range

Current $1.38

52-week range

Current $1.38

Open
$1.38
Previous close
$1.38
Volume
435.91K
0.39× average
Average volume
1.11M
Average daily volume
Market cap
147.83M USD
Beta
1.49
Market reference 1
50-day average
$1.2144
+13.64% above average
200-day average
$1.1362
+21.46% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
162.84M USD
P/E (TTM)
-4.13×
P/B (TTM)
0.93×
P/S (TTM)
4.76×
EV / EBITDA
-4.12×
Earnings yield
-27.05%
Free cash flow yield
-21.93%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
79.43%
Operating margin
-111.63%
Net margin
-114.77%
Return on equity
-26.02%
Return on assets
-22.04%
Return on invested capital
-23.87%

Financial health

Debt / equity
0.11×
Current ratio
8.3×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends112%21%-69%-160%Gross margin, FY2021: 89.24%Gross margin, FY2022: 88.48%Gross margin, FY2023: 88.51%Gross margin, FY2024: 81.62%Gross margin, FY2025: 81.16%Operating margin, FY2021: -53.66%Operating margin, FY2022: -61.82%Operating margin, FY2023: -116.98%Operating margin, FY2024: -132.54%Operating margin, FY2025: -137.12%Net margin, FY2021: -56.30%Net margin, FY2022: -53.25%Net margin, FY2023: -91.85%Net margin, FY2024: -106.29%Net margin, FY2025: -135.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 89.24%. Gross margin FY2022 88.48%. Gross margin FY2023 88.51%. Gross margin FY2024 81.62%. Gross margin FY2025 81.16%. Operating margin FY2021 -53.66%. Operating margin FY2022 -61.82%. Operating margin FY2023 -116.98%. Operating margin FY2024 -132.54%. Operating margin FY2025 -137.12%. Net margin FY2021 -56.30%. Net margin FY2022 -53.25%. Net margin FY2023 -91.85%. Net margin FY2024 -106.29%. Net margin FY2025 -135.14%.

Income trends

Revenue

33.03M USD-14.50%

Operating income

−45.29M USD+11.55%

Net income

−44.63M USD-8.71%
Income trends across reported periods53.81M USD15.62M USD−22.56M USD−60.74M USDRevenue, FY2021: 33.89M USDRevenue, FY2022: 44.26M USDRevenue, FY2023: 41.29M USDRevenue, FY2024: 38.63M USDRevenue, FY2025: 33.03M USDOperating income, FY2021: −18.19M USDOperating income, FY2022: −27.36M USDOperating income, FY2023: −48.3M USDOperating income, FY2024: −51.2M USDOperating income, FY2025: −45.29M USDNet income, FY2021: −19.08M USDNet income, FY2022: −23.57M USDNet income, FY2023: −37.92M USDNet income, FY2024: −41.06M USDNet income, FY2025: −44.63M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 33.89M USD. Revenue FY2022 44.26M USD. Revenue FY2023 41.29M USD. Revenue FY2024 38.63M USD. Revenue FY2025 33.03M USD. Operating income FY2021 −18.19M USD. Operating income FY2022 −27.36M USD. Operating income FY2023 −48.3M USD. Operating income FY2024 −51.2M USD. Operating income FY2025 −45.29M USD. Net income FY2021 −19.08M USD. Net income FY2022 −23.57M USD. Net income FY2023 −37.92M USD. Net income FY2024 −41.06M USD. Net income FY2025 −44.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue33.03M USD38.63M USD41.29M USD44.26M USD33.89M USD
Cost of goods sold6.22M USD7.1M USD4.74M USD5.1M USD3.65M USD
Gross profit26.8M USD31.53M USD36.55M USD39.16M USD30.25M USD
Research and development20.82M USD22.23M USD23.82M USD19.51M USD15.41M USD
Selling, general, and administrative47.04M USD56.35M USD57.04M USD44.48M USD31.68M USD
Operating expenses72.09M USD82.72M USD84.85M USD66.52M USD48.44M USD
Interest income7.27M USD10.14M USD10.38M USD3.92M USD150.8K USD
Interest expense———126.9K USD1.04M USD
Depreciation and amortization5.14M USD4.79M USD4.17M USD2.7M USD1.42M USD
Operating income−45.29M USD−51.2M USD−48.3M USD−27.36M USD−18.19M USD
Net income−44.63M USD−41.06M USD−37.92M USD−23.57M USD−19.08M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+20.05%
11 comparable reports
Latest EPS result
-0.08
Estimate -0.09 · Beat by 11.11%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.08-0.12-0.16Q1 '25BeatQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.1, estimate -0.12, surprise +16.67%, Beat. Q2 2025, reported May 7, 2025: actual -0.1, estimate -0.1, surprise 0.00%, Met estimate. Q3 2025, reported Aug 6, 2025: actual -0.12, estimate -0.1, surprise -20.00%, Miss. Q4 2025, reported Nov 12, 2025: actual -0.12, estimate -0.11, surprise -9.09%, Miss. Q1 2026, reported Mar 24, 2026: actual -0.06, estimate -0.08, surprise +25.00%, Beat. Q2 2026, reported May 12, 2026: actual -0.04, estimate -0.1, surprise +60.00%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.08, estimate -0.09, surprise +11.11%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.81M9.23M7.66M6.09MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 8.69M USD, estimate 9.27M USD, surprise -6.24%, Miss. Q2 2025, reported May 7, 2025: actual 10.39M USD, estimate 9.57M USD, surprise +8.59%, Beat. Q3 2025, reported Aug 6, 2025: actual 8.51M USD, estimate 10.36M USD, surprise -17.89%, Miss. Q4 2025, reported Nov 12, 2025: actual 6.83M USD, estimate 9.4M USD, surprise -27.37%, Miss. Q1 2026, reported Mar 24, 2026: actual 7.3M USD, estimate 9.08M USD, surprise -19.64%, Miss. Q2 2026, reported May 12, 2026: actual 9.65M USD, estimate 7.28M USD, surprise +32.50%, Beat. Q3 2026, reported Aug 12, 2026: actual 7.27M USD, estimate 6.51M USD, surprise +11.76%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate 7.03M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.00

334.78% upside
Past 12 months12-month forecastHigh $6.00Average $6.00Low $6.00

Rating distribution

6 ratings
Strong buy00%
Buy467%
Hold233%
Sell00%
Strong sell00%

MXCT news

globenewswire.com

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and…

Read source
marketbeat.com

MaxCyte Q2 Earnings Call Highlights

MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases…

Read source
seekingalpha.com

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

Read source
zacks.com

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.

Read source
globenewswire.com

MaxCyte Reports Second Quarter 2026 Financial Results

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately…

Read source
globenewswire.com

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of…

Read source

MXCT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MXCT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.88M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.28M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
297.08K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%

Continue in GoAI

Research MXCT

research.disclaimer